Agilent Technologies, Picometrics Technologies to Offer CE–LIF–MS Systems
Combined technologies from Agilent Technologies and Picometrics Technologies are designed for large–molecule analysis.
Agilent Technologies has signed a co-marketing agreement with Picometrics Technologies offer combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection, and mass spectrometry (MS).
A number of Agilent products can be combined with Picometrics ZETALIF LED and ZETALIF LASER instruments, including Agilent’s Capillary Electrophoresis and CE/MS technologies, as well as HPLC/UHPLC solutions.
The platform is suited for the research and development of complex large-molecule biopharmaceutical compounds, the companies report.
Source: Agilent Technologies
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
